The use of validated biomarkers that are currently mainly related to tumour genetics and their landscape, such as TMB, mismatch repair deficiency and PD-L1 expression level, in combination with novel emerging biomarkers linked to the tumour immune infiltration status and TME will help physicians to plan the most appropriate therapeutic interventions, on a case-by-case basis, by identifying which patients are most likely to benefit from the treatment and moving toward a more personalized care. This evidence concerns the gene CD274 and hyperinsulinemic hypoglycemia, familial, 4.